Clopidogrel resistance: Role of body mass and concomitant medications

International Journal of Cardiology

Volumn 120, Issue 2, 2007, Pages 188-192

  Feher, Gergely ^a   Koltai, Katalin ^a   Alkonyi, Balint ^a   Papp, Elod ^a   Keszthelyi, Zsuzsa ^a   Kesmarky, Gabor ^a   Toth, Kalman ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Antiplatelet agents and therapy; Cardiovascular diseases; Prevention; Thrombo embolic diseases

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELL ADHESION MOLECULE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HISTAMINE H2 RECEPTOR ANTAGONIST; NITRIC ACID DERIVATIVE; PADGEM PROTEIN; PHOSPHODIESTERASE INHIBITOR; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; STATINE DERIVATIVE; TRIMETAZIDINE; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; FEMALE; FLOW KINETICS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE; THROMBOCYTE AGGREGATION;

BENZODIAZEPINES; BODY MASS INDEX; DRUG INTERACTIONS; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; THROMBOEMBOLISM; TICLOPIDINE;

EID: 34447282174     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.09.014     Document Type: Article

References (30)

1. McNicol A., and Israels S.J. Platelets and anti-platelet therapy. J Pharmacol Sci 93 (2003) 381-396
2. Wang T.H., Bhatt D.L., and Topol E.J. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27 (2006) 647-654
3. Nguyen T.A., Diodati J.G., and Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 19 45 (2005) 1157-1164
4. Wiviott S.D., and Antman E.M. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation 109 (2004) 3064-3067
5. Born G.V.R., and Cross M. The aggregation of blood platelets. J Physiol (1963) 168-178
6. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 17 (1957) 237-246
7. Toth K., Ernst E., Habon T., Horvath I., Juricskay I., and Mozsik Gy. Hemorheological and hemodynamical effects of fish oil (Ameu) in patients with ischemic heart disease and hyperlipoproteinemia. Clin Hemorheol 15 (1995) 867-875
8. Klose H.J., Volger E., Brechtelsbauer H., Heinich L., and Schmid-Schonbein H. Microrheology and light transmission of blood. Pflugers Arch 333 (1972) 126-139
9. Toth K., Wenby R.B., and Meiselman H.J. Inhibition of polymer-induced red blood cell aggregation by poloxamer 188. Biorheology 37 (2000) 301-312
10. Goodall A.H., Jarvis J., Chand S., et al. An immunoradiometric assay for human factor VIII/von Willebrand factor (VIII:vWf) using monoclonal antibody that defines a functional epitope. Br J Hematol 59 (1985) 565-577
11. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340 (1999) 115-126
12. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 86 (2001) 222-232
13. Conley P.B., and Delaney S.M. Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis. Curr Opin Hematol 10 (2003) 333-338
14. A randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996) 1329-1339
15. Jaremo P., Lindahl T.L., Fransson S.G., and Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 252 (2002) 233-238
16. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
17. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting should clopidogrel loading-dose be weight adjusted?. J Invasive Cardiol 16 (2004) 169-174
18. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study. J Invasive Cardiol 16 (2004) 551-552
19. Longstreth K.L., and Wentz J.R. High-dose clopidogrel loading in percutaneous coronary intervention. Ann Pharmacother 39 (2005) 918-922
20. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3064-3067
21. Patrono C., Coller B., FitzGerald G.A., Hirsh J., and Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 234S-264S
22. Lau W.C., Waskell L.A., Watkins P.B., et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation a new drug-drug interaction. Circulation 107 (2003) 32-37
23. Serebruany V.L., Steinhubl S.R., and Hennekens C.H. Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested. Circulation 107 (2003) 1568-1569
24. Sarlis N.J., and Gourgiotis L. Hormonal effects on drug metabolism through the CYP system: perspectives on their potential significance in the era of pharmacogenomics. Curr Drug Targets Immune Endocr Metabol Disord 5 (2005) 439-448
25. Spina E., Scordo M.G., and D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 17 5 (2003) 517-538
26. Masica A.L., Mayo G., and Wilkinson G.R. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ther 76 (2004) 341-349
27. Lau W.C., Gurbel P.A., Watkins P.B., et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109 (2004) 166-171
28. Rajtar G., Zolkowska D., and Kleinrok Z. Effect of diazepam and clonazepam on the function of isolated rat platelet and neutrophil. Med Sci Monit 8 (2002) 37-44
29. Afshar-Kharghan V., and Thiagarajan P. Leukocyte adhesion and thrombosis. Curr Opin Hematol 13 (2006) 34-39
30. Kesmarky G., Toth K., Habon L., Vajda G., and Juricskay I. Hemorheological parameters in coronary artery disease. Clin Hemorheol Microcirc 18 (1998) 245-251